DTE vs ESPR
DTE (DTE) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
DTE (DTE) common stock.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
DTE does not have a complete income-statement cache yet.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
DTE currently screens at market cap $0. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the DTE and ESPR stock pages for the full models.
Not investment advice.